USD
+$0.00
(+0.00%
)At Close (As of Sep 18, 2025)
$2.11B
Market Cap
-
P/E Ratio
-5.14
EPS
$33.86
52 Week High
$22.36
52 Week Low
HEALTHCARE
Sector
Field | Value (EUR) |
---|---|
Gross Profit | -$95M |
Total Revenue | $276M |
Cost Of Revenue | $370M |
Costof Goods And Services Sold | $370M |
Operating Income | -$188M |
Selling General And Administrative | $117M |
Research And Development | $335M |
Operating Expenses | $94M |
Investment Income Net | - |
Net Interest Income | $89M |
Interest Income | $90M |
Interest Expense | $911K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $35M |
Income Before Tax | -$3.1M |
Income Tax Expense | $1.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$1.3M |
Comprehensive Income Net Of Tax | - |
Ebit | -$188M |
Ebitda | -$153M |
Net Income | $74M |
Field | Value (EUR) |
---|---|
Total Assets | $4.1B |
Total Current Assets | $3.3B |
Cash And Cash Equivalents At Carrying Value | $64M |
Cash And Short Term Investments | $64M |
Inventory | $51M |
Current Net Receivables | $47M |
Total Non Current Assets | $796M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $165M |
Intangible Assets Excluding Goodwill | $165M |
Goodwill | $70M |
Investments | - |
Long Term Investments | $253M |
Short Term Investments | $3.1B |
Other Current Assets | $123M |
Other Non Current Assets | - |
Total Liabilities | $1.2B |
Total Current Liabilities | $335M |
Current Accounts Payable | $98M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $3.5M |
Total Non Current Liabilities | $904M |
Capital Lease Obligations | $12M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $12M |
Other Current Liabilities | $234M |
Other Non Current Liabilities | $34M |
Total Shareholder Equity | $2.9B |
Treasury Stock | - |
Retained Earnings | -$134M |
Common Stock | $294M |
Common Stock Shares Outstanding | $66M |
Field | Value (EUR) |
---|---|
Operating Cashflow | -$320M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $35M |
Capital Expenditures | $82M |
Change In Receivables | - |
Change In Inventory | $23M |
Profit Loss | - |
Cashflow From Investment | $221M |
Cashflow From Financing | -$4.9M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $74M |
Field | Value (EUR) |
---|---|
Gross Profit | -$95M |
Total Revenue | $276M |
Cost Of Revenue | $370M |
Costof Goods And Services Sold | $370M |
Operating Income | -$188M |
Selling General And Administrative | $117M |
Research And Development | $335M |
Operating Expenses | $94M |
Investment Income Net | - |
Net Interest Income | $89M |
Interest Income | $90M |
Interest Expense | $911K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $35M |
Income Before Tax | -$3.1M |
Income Tax Expense | $1.8M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$1.3M |
Comprehensive Income Net Of Tax | - |
Ebit | -$188M |
Ebitda | -$153M |
Net Income | $74M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.